-
Mashup Score: 1
An abstract is unavailable.
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Following promising phase 1 study results, the combination of selinexor and ruxolitinib is being evaluated in a phase 3 trial in patients with myelofibrosis.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A phase 3 clinical trial is assessing the efficacy and safety of #selinexor + #ruxolitinib in JAKi-naïve patients with #myelofibrosis. #mpnsm https://t.co/yTg1kjxV6a
-
-
Mashup Score: 1Managing Adverse Events With Selinexor in R/R Multiple Myeloma - 2 year(s) ago
During a Targeted Oncology™ Case-Based Roundtable™ event, Sumit Madan, MD, discussed with participants what challenges they face using selinexor in patients with relapsed/refractory multiple myeloma. This is the second of 2 articles based on this event.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Sumit Madan, MD, discussed challenges when using #selinexor in patients with relapsed/refractory multiple myeloma. #mmsm | @MDAndersonNews https://t.co/H4yD7FdENW
-
-
Mashup Score: 0
Researchers are backing further investigation of 60 mg selinexor plus ruxolitinib based on positive phase 1/2 findings presented at the AACR Annual Meeting 2023.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Once-weekly #selinexor 60 mg + #ruxolitinib achieved rapid and deep spleen responses that were sustained and robust symptom improvements in patients with treatment-naïve #myelofibrosis. #AACR2023 #mpnsm | @cityofhope https://t.co/dF1zDtwcQ6
-
-
Mashup Score: 0
Srdan Verstovsek, MD, reviews data presented at ASH 2022 on combination ruxolitinib and selinexor for the frontline treatment of myelofibrosis.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Srdan Verstovsek, MD, reviews data presented at ASH 2022 on combination #ruxolitinib and #selinexor for the frontline treatment of #myelofibrosis. #mpnsm | @MDAndersonNews https://t.co/kRlYhgBxPS
-
-
Mashup Score: 1
Dr Joshua Richter describes the mechanism of action of XPO1 inhibitor selinexor and its use in treating multiple myeloma.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Listen to Joshua Richter, MD, describe the mechanism of action of XPO1 inhibitor #selinexor and its use in treating #multiplemyeloma. #mmsm @TischCancer @IcahnMountSinai @JoshuaRichterMD https://t.co/zqjLZwGt8Y
-
-
Mashup Score: 0Forsberg Explains How Selinexor Fits Into Sequencing Therapies in R/R Multiple Myeloma - 3 year(s) ago
During a Targeted Oncology case-based roundtable event, Peter Forsberg, MD, discussed data from several trials of selinexor in patients with relapsed/refractory multiple myeloma.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
During a Targeted Oncology case-based roundtable event, Peter Forsberg, MD, discussed data from several trials of #selinexor in patients with relapsed/refractory #multiplemyeloma. #mmsm | @CUCancerCenter @uchealth @ForsbergMD https://t.co/3fYT1zDjew https://t.co/CfPjVOTuue
-
-
Mashup Score: 1Between The Lines: Once Weekly Selinexor, Carfilzomib & Dexamethasone in Carfilzomib Non-Refractory Multiple Myeloma Patients - 3 year(s) ago
Dr. Joseph Mikhael and Dr. Hakan Kaya review key efficacy and safety data for the combination of Selinexor, Carfilzomib and Dexamethasone in R/R MM and discuss optimal dosing and adverse event management strategies for selinexor.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Joseph Mikhael, MD, and Hakan Kaya, MD, review key efficacy and safety data for the combination of XRd in R/R multiple myeloma and discuss optimal dosing and adverse event management strategies for #selinexor. #mmsm | @jmikhaelmd https://t.co/zc5ugzR2V4
-
-
Mashup Score: 3
Dr Joshua Richter and Dr Peter Forsberg review key trial data and dosing strategies for selinexor based combinations.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Joshua Richter, MD, and Peter Forsberg, MD, review key trial data and dosing strategies for selinexor-based combinations. #mmsm #selinexor | @JoshuaRichterMD @ForsbergMD https://t.co/9ffjkruKt2
-
-
Mashup Score: 3Selinexor: Clinical Pearls for Current and Future Use in R/R MM - 3 year(s) ago
Dr Joseph Mikhael and Dr Hakan Kaya provide advice for community oncologists who use selinexor and discuss the future of selinexor in patients with R/R MM.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Dr Joseph Mikhael and Dr Hakan Kaya provide advice for community oncologists who use selinexor and discuss the future of selinexor in patients with R/R MM. #mmsm #selinexor | @jmikhaelmd https://t.co/9JIEFrRK0X
-
Results of the Phase III study showed a substantial increase in PFS among #endometrialcancer patients in the TP53 WT subgroup receiving #selinexor (median 27.4 months) versus those receiving placebo (median 5.2 months). https://t.co/awq0VdtKyB #CancerResearch https://t.co/MoLiatoUsr